MKI67 and neoplasm: Furthermore, NETTER-2 confirmed the relevant benefits in survival and tumor response of Luthatera® combined with octreotide LAR 30 mg/28 days compared to octreotide LAR 60 mg/28 days alone (control arm), as first-line treatment in advanced, higher grade 2 (Ki67 ≥ 10% and ≤20%) and grade 3 (Ki67 > 20% and ≤55%), SSTR-positive GEP-NETs.